Pricing Log in Create free account
Friday 6 November 2026 Export TVTX’s income statement to Excel — free account

Travere Therapeutics, Inc.

TVTX Healthcare Biotechnology

Travere Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $490.7 million, up 110.5% from fiscal 2024.

Revenue
+36.2%
EPS
−290.7%
Free cash flow
+6,379.8%
Total debt
+93.8%

Quarter to September 2026, against a year earlier

49.45 0.58 +1.19%
Market cap
$4.7B
P/E
0.0×
Fwd P/E
−145×
Dividend yield
—
F-score
6/9
Altman Z
1.78
Beneish M
−1.74
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 109.70
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell 5 3 12 1 12 10 2 — 1 9 1 —
Insider Ownership 1.55%

Capital & Financial Ratios $m

Size
Market Cap 4,690.00
Revenue ttm 651.03
Net income ttm (121.51)
Free cash flow ttm 85.35
Net debt Q 131.69
Valuation
P/E 0.00
Forward P/E (145.00) (negative: loss-making)
Price / sales 7.19
Forward P/S Powerpack
Price / FCF 55.27
Price / book 207.20 (above 6: high)
Financial health
Current ratio Q 3.00 (at or above 1.5: strong)
Debt / equity Q 26.72 (above 2: weak)
Interest coverage Q (31.82)
Growth
Revenue growth Q +36.22% (above 0%: growing)
Operating income growth Q −373.17% (below 0%: shrinking)
EPS, this year −180.06% (below 0%: weak)
EPS, next year A +457.46% (at or above 15%: strong)
Revenue, next year A +47.50% (at or above 10%: strong)
EPS, past 5 yrs —
EPS, next 5 yrs A —

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 7.4×, against a ten-year median of 4.7×; over the ten years it ranged from 1.7× in 2019 to 17.0× in 2023.
P/S against its own 10 years 73.13%
10-year low 10-year high
P/B against its own 10 years 96.70%
10-year low 10-year high
EV/Sales against its own 10 years 78.45%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 567 371 323 472
Receivables 21 27 80 108
Inventory 9 6 6 11
Other — — — —
617 417 438 633
2023 2024 2025 Q'26
Payables 42 24 25 15
ST’ Debt — — — —
Other 5 17 3 2
178 201 160 211

Compound Annual Growth %

10y 5y 3y
Sales 17.25% 19.87% 64.89%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value (9.16%) (11.48%) 38.90%

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate −0.25 Actual −0.55

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q4 FY25 0.03 0.03 Met by 0.00
Q1 FY26 −0.30 −0.39 Miss by 0.09
Q2 FY26 −0.14 −0.37 Miss by 0.23
Q3 FY26 −0.25 −0.55 Miss by 0.30
Q4 FY26 0.27 — Reports 18 February 2027

EPS $

Mar Jun Sep Dec Year
’26 (0.40) (0.37) (0.55) — —
’25 (0.47) (0.14) 0.28 0.03 (0.29)
’24 (1.76) (0.91) (0.70) (0.73) (4.08)
’23 (1.27) (1.13) 1.97 (1.18) (1.50)
’22 (1.20) (1.05) (1.09) (1.03) (4.37)
’21 (0.96) (0.64) (0.59) (0.84) (3.01)
’20 0.02 (0.58) (0.44) (2.37) (3.56)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 127 170 225 — —
’25 82 114 165 130 491
’24 41 54 63 75 233
’23 31 32 37 45 145
’22 48 54 28 (21) 109
’21 47 55 68 (38) 132
’20 48 48 51 51 198
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (40) 58 98 — —
’25 (42) 5 14 61 38
’24 (119) (40) (43) (36) (237)
’23 (81) (69) (59) (70) (280)
’22 (55) (37) (40) (55) (186)
’21 (26) 6 32 (27) (15)
’20 (29) (6) 7 (14) (43)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (63) 37 69 — —
’25 (54) (7) (1) 41 (20)
’24 (125) (52) (51) (45) (274)
’23 (109) (73) (64) (76) (322)
’22 (61) (48) (47) (59) (215)
’21 (36) 2 27 (32) (39)
’20 (34) (11) 0 (22) (67)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 134 155 164 175 198 132 109 145 233 491 651 +15.6% 724 1,076 1,360 +40.5%
Gross margin, % 96.59 97.67 96.63 97.01 96.91 97.10 95.96 92.12 96.68 97.89 98.53 +1.3 pt
EBT (58) (58) (102) (146) (189) (217) (331) (376) (321) (49) (160) (1.7%)
EBT margin, % (43.10) (37.67) (62.02) (83.52) (95.19) (164.51) (302.54) (258.96) (137.45) (10.04) (24.53) +33.1 pt
Net income (48) (60) (103) (146) (169) (180) (278) (111) (322) (26) (122) (6.7%)
Per share, $
Per share, $ Revenue 3.61 4.00 4.06 4.14 4.17 2.20 1.72 1.96 2.96 5.50 6.88 +4.8%
Earnings (1.29) (1.54) (2.54) (3.46) (3.56) (3.01) (4.37) (1.50) (4.08) (0.29) (1.29) (15.3%)
Cash flow (0.09) 0.19 (0.62) (1.37) (0.90) (0.25) (2.92) (3.77) (3.01) 0.42 1.87 n/m
Capex (0.32) (0.36) (0.49) (0.37) (0.52) (0.40) (0.45) (0.57) (0.46) (0.65) (0.96) +8.1%
Free cash flow (0.42) (0.17) (1.10) (1.74) (1.42) (0.65) (3.37) (4.34) (3.47) (0.23) 0.90 (6.4%)
Book value 8.32 7.56 7.87 5.22 4.44 5.05 0.67 2.70 0.75 1.29 0.24 (18.7%)
Shares, m 37 39 40 42 48 60 64 74 79 89 92 +10.3%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
P/S 5.11 5.62 5.57 3.43 6.53 14.09 12.03 4.89 5.89 6.95 7.19 7.0
P/B 2.22 2.97 2.88 2.72 6.14 6.15 30.74 3.54 23.26 29.69 207.20 11.0
EV/Sales 3.53 3.97 3.89 2.32 5.80 11.61 11.35 3.58 5.63 6.92 7.39 5.9
EV/FCF (30.66) (93.19) (14.30) (5.52) (17.08) (39.31) (5.78) (1.61) (4.80) (161.30) 56.83 (37.4)
Cash, $m
Cash, $m Operating cash flow (3) 7 (25) (58) (43) (15) (186) (280) (237) 38 177 n/m
Capex (12) (14) (20) (16) (25) (24) (29) (42) (36) (58) (91) +19.3%
Free cash flow (15) (7) (45) (74) (67) (39) (215) (322) (274) (20) 85 +3.2%
Balance, $m
Balance, $m Working capital 249 240 391 334 318 459 344 439 216 278 423 +1.2%
Net debt (211) (256) (276) (194) (146) (326) (75) (190) (60) (11) 132 (27.9%)
Shareholders’ equity 308 293 318 221 211 302 43 201 59 115 23 (10.4%)
Returns, %
Returns, % ROA (9.23) (11.42) (16.70) (22.29) (27.95) (26.02) (38.43) (15.24) (46.50) (4.26) (17.52) +5.0 pt
ROIC (37.78) (89.46) (119.67) (311.81) (169.48) 0.00 0.00 (2,161.70) 0.00 (37.84) (54.08) (0.1) pt
ROE (15.76) (19.88) (33.59) (54.29) (78.37) (70.17) (161.46) (91.44) (247.45) (29.38) (252.75) (13.6) pt
People
People Employees 135 173 214 221 262 310 462 380 385 497 — +15.6%
Revenue/emp, $m 0.99 0.90 0.77 0.79 0.76 0.43 0.24 0.38 0.61 0.99 — 0.0%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 6 Nov 2026

Travere Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
MANE Veradermics Incorporated $5.4B — (loss-making) — — n/m −8.81% (below 0%: shrinking) — 0.00% Compare
COGT Cogent Biosciences, Inc. $5.1B — (loss-making) — (loss-making) −69.41% (below 0%: shrinking) n/m −42.01% (below 0%: shrinking) 0.00% 0.00% Compare
CRSP CRISPR Therapeutics AG $4.7B — (loss-making) — (loss-making) +1,325.08% (above 0%: growing) n/m −6.36% (below 0%: shrinking) 100.00% (1,026.48%) Compare
TVTX Travere Therapeutics, Inc. $4.7B — (loss-making) — (loss-making) +36.22% (above 0%: growing) n/m +6,379.75% (above 0%: growing) 98.72% (30.33%)
DNTH Dianthus Therapeutics, Inc. $4.6B — (loss-making) — (loss-making) +205.56% (above 0%: growing) n/m −65.91% (below 0%: shrinking) 100.00% (4,832.40%) Compare
ERAS Erasca, Inc. $4.6B — (loss-making) — — n/m −4.67% (below 0%: shrinking) 0.00% 0.00% Compare
LEGN Legend Biotech Corporation Sponsored ADR $4.4B — (loss-making) — (loss-making) +51.90% (above 0%: growing) n/m −26.79% (below 0%: shrinking) 64.54% 14.37% Compare
EWTX Edgewise Therapeutics, Inc. $4.2B 4.9× — — n/m −30.24% (below 0%: shrinking) 0.00% 0.00% Compare
DFTX Definium Therapeutics, Inc. $4.1B — (loss-making) — — n/m −78.31% (below 0%: shrinking) 0.00% 0.00% Compare
Median of peers $4.6B — — +128.73% — −28.51% 0.00% 0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 6 April 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 8.46m 24.50m 140.19
2024 5.20m 10.95m 122.68
2023 7.57m 885.49k 63.31
2022 5.75m 687.24k 148.10
2021 5.74m 6.56m 218.59

Ownership

Directors and executive officers, together 4.44%
Janus Henderson Investors 11.48%
Fidelity Management & Research Company (FMR) LLC 11.45%
BlackRock, Inc. 7.25%
The Vanguard Group 6.49%
State Street Investment Management 5.15%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Travere Therapeutics, Inc. (TVTX) Latest News

3 Nov

Impact 3 · · Moby
Impact 3 · · Simply Wall St.

2 Nov

Impact 3 · · The Motley Fool transcript
Impact 3 · · MarketBeat transcript
Impact 3 · · Zacks
Impact 3 · · Business Wire

28 Oct

Impact 3 · · Zacks

26 Oct

Impact 3 · · Business Wire earnings

23 Oct

Impact 4 · · Business Wire

7 Oct

Impact 4 · · Simply Wall St.

2 Oct

Impact 4 ·

23 Sep

Impact 4 ·

22 Sep

Impact 4 · · Simply Wall St.

21 Sep

Impact 4 · · Business Wire

8 Sep

Impact 4 ·

18 Aug

Impact 4 · · MarketBeat

11 Aug

Impact 3 · · The Motley Fool transcript

7 Aug

Impact 3 ·
Impact 3 ·

6 Aug

Impact 3 ·
Impact 3 · · Moby

5 Aug

Impact 4 · transcript

4 Aug

Impact 3 · · MarketBeat transcript
Impact 3 ·
Impact 3 ·

27 Jul

Impact 4 ·

7 Jul

Impact 3 ·

4 Jun

Impact 3 · · Business Wire

2 Jun

Impact 4 · · PR Newswire
Impact 3 · · Stocktwits

TVTX metrics, ten years each

stockrow.com/TVTX · Data as of Nov 6, 2026 · For information only; not investment advice. · © 2026 stockrow.com